- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07650110
Biological Collection of the Rare Diseases of the Brain and Eye Vessels Cohort - 2 (B-MRVC2)
Collection Biologique de la Cohorte Des Maladies Rares Des Vaisseaux du Cerveau et de l'œil - 2
CERVCO is the French National Reference Centre for Rare Cerebrovascular and Retinal Diseases, accredited by the Ministry of Health since 2005. Since 2017, CERVCO has coordinated the MRVC cohort, a prospective cohort of patients with rare vascular diseases of the brain and retina, and established the associated B-MRVC biobank in 2020 to support translational research and biomarker discovery.
Due to the rarity and heterogeneity of these disorders, centralized longitudinal collection of clinical data and biological samples is essential to improve understanding of disease mechanisms, identify biomarkers of progression and prognosis, and facilitate the development of new diagnostic and therapeutic approaches.
The present study aims to expand this longitudinal biobank, enable national and international collaborative research through controlled sample sharing, and establish reference control samples to support biomarker validation.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiekontakt
- Navn: Hugues Chabriat, MD PhD
- Telefonnummer: +33 +33 1 49 95 25 93
- E-mail: hugues.chabriat@aphp.fr
Undersøgelse Kontakt Backup
- Navn: Jérôme Lambert
- Telefonnummer: +33 +33 1 42 49 97 42
- E-mail: jerome.lambert@u-paris.fr
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
- Voksen
- Ældre voksen
Tager imod sunde frivillige
Beskrivelse
Inclusion Criteria:
For the group of patients with MVCR:
- Patients aged between 18 and 80 years at the time of inclusion
- Diagnosis confirmed by the detection of a pathogenic mutation in the NOTCH3 gene characteristic of CADASIL, or in another gene responsible for other forms of monogenic cSVD (such as the COL4A1, COL4A2 and HTRA1 genes) or a confirmed diagnosis of MOYA-MOYA (arteriography and/or genetic testing) or cavernoma, cerebral venous thrombosis or a cerebral vascular malformation, including cavernomas
- Covered by social security or an equivalent scheme
- Written consent.
- Patient included in the MVCR cohort For control group
- Subject aged between 18 and 80 at the time of inclusion.
- Written consent.
- Blood pressure < 140/90 mmHg without treatment or < 130/80 mmHg if treated and stable for ≥3 months
- Covered by social security or a similar scheme
- Strictly normal neurological examination (NIHSS=0; no focal deficit)
- Normal cognitive examination: MMSE ≥ 26
Exclusion criteria :
Common exclusion criteria for patients and control subjects:
A person referred to in Articles L. 1121-5 to L. 1121-8 and L. 1122-12 of the Public Health Code, defined as:
- Pregnant women, women in labour or breastfeeding women
- Persons deprived of their liberty by judicial or administrative decision
- Persons hospitalised without consent and not subject to a legal protection measure, and persons admitted to a health or social care facility for purposes other than research
- Minors
- Adults subject to a legal protection measure (guardianship, curatorship or judicial protection), adults unable to give consent and not subject to a legal protection measure
- Individuals subject to a withdrawal period for another research study
- Patients participating in another interventional research study
- Acute or chronic infectious disease
Specific exclusion criteria for control subjects
- Any identified extra- or intracranial vascular pathology requiring specific management
- Known cardiovascular disease (coronary artery disease, arterial disease, atrial fibrillation, heart failure)
- Neurological history: stroke, TIA, intracranial haemorrhage, meningitis/encephalitis, head injury with loss of consciousness >30 mins,
- Multiple sclerosis, neurodegenerative disease, active epilepsy,
- Current or former smoking (more than 10 pack-years)
- Diabetes
- Antithrombotic or lipid-lowering treatment
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Andet
- Tildeling: Ikke-randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Andet: MVCR patients
Patient with a confirmed diagnosis of rare cerebro-vacular disease
|
Additional blood collection
|
|
Andet: Control group
Healthy controls / volunteers s with no cardiovascular or neurovascular disease
|
For healthy volunteers: neurological evaluation, blood and urine sampling
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Comparative analysis of proteins
Tidsramme: At inclusion
|
Comparative analysis of proteins and candidate biomarkers in serum or plasma between patients with a rare brain disorder and control subjects
|
At inclusion
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Measurement of proteins and biomarkers
Tidsramme: Up to 5 years
|
Up to 5 years
|
|
|
Occurrence of a significant event indicating disease progression
Tidsramme: Up to 5 years
|
Stroke, cognitive decline, progressive markers in brain or retinal imaging
|
Up to 5 years
|
|
Inter-method variability of assays assessed by measures of agreement between techniques
Tidsramme: Up to 5 years
|
Up to 5 years
|
|
|
Protein/biomarker assays according to the different conditions involved
Tidsramme: Up to 5 years
|
Up to 5 years
|
|
|
Protein/biomarker assays according to sex and age
Tidsramme: Up to 5 years
|
Up to 5 years
|
Samarbejdspartnere og efterforskere
Datoer for undersøgelser
Studer store datoer
Studiestart (Anslået)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Cavernous sinus syndromer
- Cerebrovaskulære lidelser
- Hjernesygdomme
- Sygdomme i centralnervesystemet
- Sygdomme i nervesystemet
- Karsygdomme
- Hjerte-kar-sygdomme
- Patologiske processer
- Neoplasmer
- Genetiske sygdomme, medfødte
- Neoplasmer efter histologisk type
- Hjerneinfarkt
- Hjerneiskæmi
- Infarkt
- Nekrose
- Hæmatologiske sygdomme
- Demens
- Medfødte abnormiteter
- Kardiovaskulære abnormiteter
- Hæmostatiske lidelser
- Hæmoragiske lidelser
- Neoplasmer, vaskulært væv
- Misdannelser i nervesystemet
- Iskæmi
- Intrakranielle arterielle sygdomme
- Slag
- Cerebrale arterielle sygdomme
- Vaskulære misdannelser
- Cerebralt infarkt
- Cerebrale småkarsygdomme
- Demens, Vaskulær
- Hæmangiom
- Medfødte, arvelige og neonatale sygdomme og abnormiteter
- Patologiske tilstande, tegn og symptomer
- Hemiske og lymfatiske sygdomme
- CADASIL
- Hæmangiom, hule
- Vaskulære misdannelser i centralnervesystemet
Andre undersøgelses-id-numre
- APHP260095
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med CADASIL
-
National Heart, Lung, and Blood Institute (NHLBI)AfsluttetKardiovaskulær sygdom | Arteriel stivhed | Kimlinjemutation i NOTCH 3-genet | Patogenese af CADASIL | Klinisk fænotype af CADASILForenede Stater
-
National Heart, Lung, and Blood Institute (NHLBI)RekrutteringKardiovaskulær sygdom | Arteriel stivhed | Kimlinjemutation i NOTCH 3-genet | Patogenese af CADASIL | Klinisk fænotype af CADASILForenede Stater
-
Perminder SachdevMelbourne Health; Royal Brisbane and Women's Hospital; The University of... og andre samarbejdspartnereRekruttering
-
National Cerebral and Cardiovascular Center, JapanAfsluttet
-
Assistance Publique - Hôpitaux de ParisRekrutteringCadasil | Angiopati; CerebralFrankrig
-
Fondazione I.R.C.C.S. Istituto Neurologico Carlo...RekrutteringCADASIL | CADASIL (diagnose)Italien, Spanien
-
Peking University First HospitalChinese Academy of SciencesRekruttering
-
Ever Neuro Pharma GmbHXClinical GmbH; idv Datenanalyse & VersuchsplanungAktiv, ikke rekrutterende
-
Assistance Publique - Hôpitaux de ParisIkke rekrutterer endnuCerebrale småkarsygdomme | CADASIL (diagnose)